$AIFF News

Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience Partners With NeuroSigma To Expand Clinician Awareness Of And Access To The Monarch eTNS System

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine

Firefly Neuroscience Collaborates With Radial To Pursue Integration Of AI-Powered Evoke EEG/ERP Platform With RadialOS, AI-Native OS For Brain Medicine

Firefly Neuroscience Announces Termination Of CFO Paul Krzywicki Effective September 24

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience And Next Health Partner To Launch Precision Cognitive Health Platform Integrating Firefly’s AI-Powered, FDA-Cleared EEG/ERP Brain Biomarker Technology With Personalized Cognitive Peptide Protocols

Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

Firefly Neuroscience Announces Identification Of Electrophysiological Biomarker For Post-Traumatic Stress Disorder Using Brain Scans Collected On FDA-510(k)-Cleared Evoke System

Firefly Neuroscience Announces Over 200K EEG/ERP Scans

Firefly Neuroscience Q4 EPS $(0.15) Up From $(0.45) YoY, Sales $412.000K Up From $63.000K YoY

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Neuroscience shares are trading higher after the company announced a public-private partnership to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury.

Firefly Neuroscience shares are trading higher after the company announced a public-private partnership to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury.

Firefly Stock Jumps On Department Of Defense Partnership

Firefly Neuroscience Partners With Department Of War To Support Assessment, Treatment Of Active-Duty U.S. Service Members And Veterans Suffering From PTSD And/Or Traumatic Brain Injury

Why Firefly Neuroscience Stock Is Soaring Today

Firefly Neuroscience shares are trading higher after the company announced that it advanced research using Resting EEG/Cognitive EEG brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder.